Haloimidazole derivatives and their use as muscarinic m3 and serotoninergic 5-ht4 receptors

The invention concerns compounds of general formula (I) wherein: R1 and/or R2 represent a halogen atom, and when one of the substituents R1 or R2 does not represent a halogen the latter represent a hydrogen atom or a C1-C4 alkyl group; R represents a C2-C6 alkenyl, a phenyl, a naphthyl, a thienyl, a pyrrolyl or furyl group, optionally substituted by one or two R4 groups; R3 and R4 represent, independently of each other, a hydrogen atom, a halogen atom, a hydroxy, a C1-C4 alkyl, C1-C4 alkoxy, cyano, nitro, C1-C2 perfluoroalkyl, a hydroxymethyl or amino group; n = 1, 2 or 3; and their salts, N-oxides and hydrates. The invention has therapeutic applications.